Article information
Resumen
La osteoporosis es una enfermedad silenciosa hasta que se presenta su principal complicación: las fracturas; con un importante costo económico y social para el paciente y el sistema de salud, constituyéndose en un verdadero problema de salud pública. Las mujeres en la etapa postmenopáusica tienen un mayor riesgo de osteoporosis y por ende de fractura. Actualmente disponemos de un variado grupo de medicamentos que, a través de diferentes mecanismos de acción, mejoran la densidad mineral ósea y disminuyen el riesgo de fractura. En el presente artículo se presenta al lector información relevante de cada uno de los medicamentos empleados en el tratamiento de esta entidad desde el punto de vista farmacológico y de efectividad clínica.
Palabras clave:
osteoporosis
fractura
menopausia
densidad mineral ósea
Summary
Osteoporosis is a silent illness until fractures appears, with a very high economic and social cost for the patient and the health system, representing a true problem of public health. Postmenopausal women have a higher risk of osteoporosis and fracture. Actually are available different drugs that through a varied mechanism of action, increase bone mineral density and reduce fracture risk. In this article we present relevant information about the pharmacology and clinical effectiveness of each one of drugs used in the treatment of osteoporosis.
Key words:
osteoporosis
fracture
menopause
bone mineral density
Full text is only aviable in PDF
Referencias
[1.]
J.A. Kanis, N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, et al.
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
Osteoporos Int, 19 (2008), pp. 399-428
[2.]
U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general (2004). http://www.surgeongeneral.gov/library/bonehealth/content.html. Acceso el 25 de febrero de 2009.
[3.]
B. Nochowitz, S. Siegert, M. Wasik.
An update on osteoporosis.
Am J Ther, 16 (2009), pp. 437-445
[4.]
P. Sambrook, C. Cooper.
Osteoporosis.
Lancet, 367 (2006), pp. 2010-2018
[5.]
C.M. Klotzbuecher, P.D. Ross, P.B. Landsman, T.A. Abbott, M. Berger.
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.
J Bone Miner Res, 15 (2000), pp. 721-739
[6.]
N.F. Ray, J.K. Chan, M. Thamer, L.J. Melton.
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation.
J Bone Miner Res, 12 (1997), pp. 24-36
[7.]
N.F. Col, M.H. Eckman, R.H. Karas, S.G. Pauker, R.J. Goldberg, E.M. Ross, et al.
Patient – specific decisions about hormone replacement therapy in postmenopausal women.
JAMA, 277 (1997), pp. 1140-1147
[8.]
S.H. Gehlbach, C. Bigelow, M. Heimisdottir, S. May, M. Walker, J.R. Kirkwood.
Recognition of vertebral fracture in a clinical setting.
Osteoporos Int, 11 (2000), pp. 577-582
[9.]
M.G. Sweet, J.M. Sweet, M.P. Jeremiah, S.S. Galazka.
Diagnosis and treatment of osteoporosis.
Am Fam Physician, 79 (2009), pp. 193-200
[10.]
E. Dennison, M.A. Mohamed, C. Cooper.
Epidemiology of osteoporosis.
Rheum Dis Clin N Am, 32 (2006), pp. 617-629
[11.]
L. Sinigaglia, M. Varenna, G. Girasole, G. Bianchi.
Epidemiology of osteoporosis in rheumatic diseases.
Rheum Dis Clin N Am, 32 (2006), pp. 631-658
[12.]
G.M. Blake, I. Fogelman.
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.
Postgrad Med J, 83 (2007), pp. 509-517
[13.]
Writing Group for the ISCD Position Development Conference.
Indications and reporting for dual-energy x-ray absorptimoetry.
J Clin Denistom, 7 (2004), pp. 37-44
[14.]
A.E. Maghraoui, C. Roux.
DXA scanning in clinical practice.
Q J Med, 101 (2008), pp. 605-617
[15.]
J.T. Lin, J.M. Lane.
Nonpharmacologic management of osteoporosis to minimize fracture risk.
Nat Clin Pract Rheumatol, 4 (2008), pp. 20-25
[16.]
P. Schwab, R. Klein.
Nonpharmacological approaches to improve bone health and reduce osteoporosis.
Curr Opin Rheumatol, 20 (2008), pp. 213-217
[17.]
S.J. Genuis, G.K. Scwalfenberg.
Picking a bone with contemporary osteoporosis management: nutrient strategies to enhance skeletal integrity.
Clin Nutrition, 26 (2007), pp. 193-207
[18.]
R. Keen.
Osteoporosis: strategies for prevention and management.
Best Pract Res Clin Rheumatol, 21 (2007), pp. 109-122
[19.]
P.P. Geusens, C.H. Roux, D.M. Reid, W.F. Lems, A. Adami, J.D. Adachi, et al.
Drugs insight: choosing a drug treatment strategy for women with osteoporosis – an evidence based clinical perspective.
Nat Clin Pract Rheumatol, 4 (2008), pp. 240-248
[20.]
National Osteoporosis Foundation.
Clinicians guide to prevention and treatment of osteoporosis.
National Osteoporosis Foundation, (2008),
[21.]
E. Stein, E. Shane.
Secondary osteoporosis.
Endocrinol Metab Clin N Am, 32 (2003), pp. 115-134
[22.]
A. Kelman.
The management of secondary osteoporosis.
Best Pract Res Clin Rheumatol, 19 (2005), pp. 1021-1037
[23.]
J. Allport.
Incidence and prevalence of medicationinduced osteoporosis: evidence based review.
Curr Opin Rheumatol, 20 (2008), pp. 435-441
[24.]
L.S. Simon.
Osteoporosis.
Clin Geriatr Med, 21 (2005), pp. 603-629
[25.]
R.G. Russel, J.E. Dunford, U. Oppermann, A. Kaawasi, P.A. Hulley, K.L. Kavanagh, et al.
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Ann NY Acad Sci, 1117 (2007), pp. 209-257
[26.]
R.R. Recker, E.M. Lewiecki, P.D. Miller, J. Reiffel.
Safety of bisphosfonates in the treatment of osteoporosis.
Am J Med, 122 (2009), pp. 22-32
[27.]
P.A. Friedman.
Agentes que modifican la homeostasia de iones minerales y el recambio de hueso.
Las bases farmacológicas de la terapéutica. 2006, pp. 1647-1675
[28.]
J.B. Imboden.
Therapies: medications.
Current Rheumatology, diagnosis and treatment, 2a,
[29.]
C. Roux.
Potential effects of bisphosfonates on bone ultraestructure.
Osteoporos Int, 20 (2009), pp. 1093-1095
[30.]
N.E. Lane.
Metabolic bone disease.
Kelly’s Testbook of Rheumatology, 8a, pp. 1579-1599
[31.]
R.G. Russel.
Bisphosfonates: from bench to bedside.
Ann NY Acad Sci, 1068 (2006), pp. 367-401
[32.]
R. Pellegrini.
Which water for alendronate administration?.
Osteoporos Int, 20 (2009), pp. 1451
[33.]
K.E. Poole, J.E. Compston.
Osteoporosis and its management.
BMJ, 333 (2006), pp. 1251-1256
[34.]
P.D. Miller.
Anti-resorptives in the management of osteoporosis.
Best Pract Res Clin Endoc Metabol, 22 (2008), pp. 849-868
[35.]
P.D. Miller.
Is there a role for bisphosfonates in chronic kidney disease?.
Semin Dial, 20 (2007), pp. 186-190
[36.]
S.L. Ruggiero, B. Mehrotra, T. Rosenberg.
Osteonecrosis of the jaw associated with the use of biphosphonates: a review of 63 cases.
J Oral Maxillofac Surg, 62 (2004), pp. 527-534
[37.]
Advisory task force on bisphosphonate-related osteonecrosis of the jaws.
American Association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaws.
J. Oral Maxillofac Surg, 65 (2007), pp. 369-376
[38.]
A.A. Khan, G.K. Sandor, E. Dore, A.D. Morrison, M. Alzhali, F. Amin, et al.
Bisphosphonate associated osteonecrosis of the jaw.
J Rheumatol, 36 (2009), pp. 478-490
[39.]
J.P. Bilezikian.
Osteonecrosis of the jaw – Do bisphosphonates pose a risk?.
NEJM, 355 (2006), pp. 2278-2281
[40.]
R.N. Goytia, A. Salama, H.S. Khanuja.
Bisphosphonates and osteonecrosis: potential treatment or serious complication?.
Orthop Clin N Am, 40 (2009), pp. 223-234
[41.]
S.L. Ruggiero, B. Mehrotra.
Bisphoshponate related osteonecrosis of the jaw: diagnosis, prevention and management.
Annu Rev Med, 60 (2009), pp. 85-96
[42.]
S.R. Majumdar.
Oral bisphosphonates and atrial fibrillation.
BMJ, 336 (2008), pp. 784-785
[43.]
H.T. Sorensen, S. Christensen, F. Mehnert, L. Pedersen, R.D. Chapurlat, S.R. Cummings, et al.
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case control study.
BMJ, 336 (2008), pp. 813-816
[44.]
N.B. Watts, S.T. Harris, H.K. Genant, R.D. Wasnich, P.D. Miller, R.D. Jackson.
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
NEJM, 322 (1990), pp. 1265-1271
[45.]
T. Storm, G. Thamsborg, T. Steiniche, H.K. Genant, O.H. Sorensen.
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in woman with postmenopausal osteoporosis.
NEJM, 323 (1990), pp. 73-79
[46.]
A. Cranney, G. Guyatt, N. Krolicki, V. Welch, L. Griffith, D. Adachi, et al.
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.
Osteoporos Int, 12 (2001), pp. 140-151
[48.]
M. McClung, B. Clemmesen, A. Daifotis, N.L. Gilchrist, J. Eisman, R.S. Weinstein, et al.
Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial.
Ann Inter Med, 128 (1998), pp. 253-261
[49.]
D. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, et al.
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Lancet, 348 (1996), pp. 1535-1541
[50.]
S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett-Connor, T.A. Musliner, et al.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial.
JAMA, 280 (1998), pp. 2077-2082
[51.]
A. Cranney, P. Tugwell, G. Wells, G. Guyatt.
Metaanalyses of therapies for postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 508-516
[52.]
T. Schnitzer, H.G. Bone, G. Crepaldi.
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis.
Aging (Milan, Italy), 12 (2000), pp. 1-12
[53.]
The alendronate once-weekly study group.
Two-years results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis.
J Bone Miner Res, 17 (2002), pp. 1988-1996
[54.]
L. Mortensen, P. Charles, J. Bekker, J. Digennaro, C. Johnston.
Risedronate increases bone mass in early postmenopausal population: two years for treatment plus one year for follow-up.
J Clin Endocrinol Metabol, 83 (1998), pp. 396-402
[55.]
I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, J.Y. Reginster.
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double blind, placebocontrolled trial BMD-MN Study Group.
J Clin Endocrinol Metabol, 85 (2000), pp. 1895-1900
[56.]
S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, M. Keller, et al.
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.
JAMA, 282 (1999), pp. 1344-1352
[57.]
J.Y. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, M.L. Brandi, B. Lund, et al.
Randomized trial the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.
Osteoporos Int, 11 (2000), pp. 83-91
[58.]
O.H. Sorensen, G.M. Crawford, M. Hulder, D.J. Hosking, C. Gennari, D. Mellstrom, et al.
Long-terms safety of risedronate: a 5 years placebo – controlled clinical experience.
Bone, 32 (2003), pp. 120-126
[59.]
J.P. Brown, D.L. Kendler, M.R. McClung, R.D. Emkey, J.D. Adachi, M.A. Bolognese.
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Calcif Tissue Int, 71 (2002), pp. 103-111
[60.]
M.K. Rizer.
Osteoporosis.
Prim Care Clin Office Pract, 33 (2006), pp. 943-951
[61.]
S. Adami.
Bisphosphnate antifracture efficacy.
Bone, 41 (2007), pp. s8-s15
[62.]
J.R. Curtis, A.O. Westfall, H. Cheng, K.G. Saag, E. Delzell.
Risendronate and alendronate intervention over three years (REALITY): minimal differences in fracture risk reduction.
Osteoporos Int, 20 (2009), pp. 973-978
[63.]
C.H. Chesnut III, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hoiseth, et al.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res, 19 (2004), pp. 1241-1249
[64.]
J.Y. Reginster, S. Adami, P. Lakatos, M. Greenwald, J.J. Stepan, S.L. Silverman, et al.
Efficacy and tolerability of oncemonthly oral inbandronate in postmenopausal osteoporosis: 2 years results from the MOBILE study.
Ann Rheum Dis, 65 (2006), pp. 654-661
[65.]
P.D. Delmas, S. Adami, C. Strugala, J.A. Stakkestad, J.Y. Reginster, D. Felsenberg.
Intravenous ibandroante injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study.
Arthritis Rheum, 54 (2006), pp. 1838-1846
[66.]
S.T. Harris, J.Y. Reginster, W.A. Blumentals, S.A. Poston, C.E. Barr, S.L. Silverman.
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The evaluation of ibandronate efficacy (VIBE) database fracture study.
Bone, 44 (2009), pp. 758-765
[67.]
S.E. Papapoulus, R.C. Schimmer.
Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Ann Rheum Dis, 66 (2007), pp. 853-858
[68.]
R. Muller, R.R. Recker.
Bisphosphonate action on bone structure and strength: preclinical and clinical evidence for ibandronate.
Bone, 41 (2007), pp. s16-s23
[69.]
R. Rizzoli, D.M. Reid.
Ibandronate: an IV injection for the treatment for postmenopausal osteoporosis.
Bone, 41 (2007), pp. s24-s28
[70.]
I.R. Reid, J.P. Brown, Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel.
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
NEJM, 346 (2002), pp. 653-661
[71.]
D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley.
Once-Year Zoledronic Acid for Treatment of Postmenopausal Osteoporosis.
NEJM, 356 (2007), pp. 1809-1822
[72.]
K.W. Lyles, C.S. Colon-Emeric, J.S. Magazines, J.D. Adachi, C.F. Pieper, C. Mautalen, et al.
The HORIZON recurrent fracture trial Zoledronic acid and clinical fractures and mortality after hip fracture.
NEJM, 357 (2007), pp. 1799-1807
[73.]
C.J. Rosen.
Postmenopausal osteoporosis.
NEJM, 353 (2005), pp. 595-603
[74.]
Y. Watanabe, H. Ohshima, K. Mizuno, C. Sekiguchi, M. Fukunaga, K. Kohri, et al.
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
J Bone Min Res, 19 (2004), pp. 1771-1778
[75.]
H. Younes, G. Farhat, G. el-Hajj Fuleihan.
Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass.
J Clin Densitometry, 5 (2002), pp. 143-149
[76.]
N.M. Mehta, A. Malootian, J.P. Gilligan.
Calcitonin for osteoporosis and bone pain.
Curr Pharm Des, 9 (2003), pp. 2569-2576
[77.]
C.H. Chesnut III, M. Azria, S. Silverman, M. Engelhardt, M. Olson, L. Mindeholm.
Salmon calciton : a review of current and future therapeutic indications.
Osteoporos Int, 19 (2008), pp. 479-491
[78.]
A. Cranney, P. Tugwell, N. Zyatruk, V. Robinson, B. Weaver, B. Shea, et al.
Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 540-551
[79.]
C.H. Chesnut III, S. Silverman, K. Andriano, H. Genant, A. Giomama, S. Harris, et al.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporosis fracture Study PROOF Study Group.
Am J Med, 109 (2000), pp. 267-276
[80.]
R.W. Downs, N.H. Bell, M.P. Ettinger, B. Walsh, M.J. Favus, B. Mako, et al.
Comparison of alendronate and intranasal calcitonin for treatment in osteoporosis in postmenopausal women.
J Clin Endocrinol Metab, 85 (2000), pp. 1783-1788
[81.]
J.C. Gallagher.
Role of estrogens in the management of postmenopausal bone loss.
Rheum Dis Clin N Am, 27 (2001), pp. 143-162
[82.]
J.A. Cauley, J. Robbins, Z. Chen, S.R. Cummings, R.D. Jackson, A.Z. LaCroix, et al.
Effects of estrogens plus progestin on risk of fracture and bone mineral density: The women's health initiative randomized trial.
JAMA, 290 (2003), pp. 1729-1738
[83.]
J.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, et al.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial; The women's health initiative steering committee.
JAMA, 291 (2004), pp. 1701-1712
[84.]
R.T. Clebowski, J. Wactawski-Wende, C. Ritenbaugh, F.A. Hubbell, J. Ascensao, R.J. Rodabough.
Estrogen plus progestin and colorectal cancer in postmenopausal women.
NEJM, 350 (2004), pp. 991-1004
[85.]
Writing group for the women's health initiative investigators.
Risk and benefits of estrogen plus progestin in healthy postmenopausal women Principal results from the women's health initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
[86.]
A. Cranney, G.A. Wells.
Hormone replacement therapy for postmenopausal osteoporosis.
Clin Geriatr Med, 19 (2003), pp. 361-370
[87.]
R. Lash, J.M. Nicholson, L. Velez, R. Van Harrison, J. McCort.
Diagnosis and management of osteoporosis.
Prim Care Clin Office Pract, 36 (2009), pp. 181-198
[88.]
Evista (inserto del empaque). Indianapolis: Eli Lilly y compañía; 2007.
[89.]
C.L. Deal, A.G. Abelson, J.J. Carey.
Management of osteoporosis.
Rheumatology, pp. 1955-1968
[90.]
B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, et al.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial.
JAMA, 282 (1999), pp. 637-645
[91.]
E.S. Siris, S.T. Harris, R. Eastell, J.R. Zanchetta, S. Goemaere, A. Diez-Perez, et al.
Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study.
J Bone Min Res, 20 (2005), pp. 1514-1524
[92.]
S. Martino, J.A. Cauley, E. Barret-Connor, T.J. Powles, J. Mershon, D. Disch, et al.
Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized clinical trial of raloxifene.
J Natl Cancer Inst, 96 (2004), pp. 1751-1761
[93.]
V.G. Vogel, J.P. Costantino, D.L. Wickerham.
Effects of tamoxifen vs raloxifene on the risk of developing breast cancer and other diseases outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.
JAMA, 295 (2006), pp. 2727-2741
[94.]
C. Deal.
Potential new drugs targets for osteoporosis.
Nat Clin Pract Rheumatol, 5 (2009), pp. 20-26
[95.]
R.L. Jilka.
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.
Bone, 40 (2007), pp. 1434-1446
[96.]
B. Cortet.
Effects of bone anabolic agents on bone ultrastructure.
Osteoporos Int, 20 (2009), pp. 1097-1100
[97.]
J.E. Compston.
Skeletal actions of intermittent parathyroid hormone: Effects on bone remodeling and structure.
Bone, 40 (2007), pp. 1447-1452
[98.]
R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, et al.
Effect of parathyroid hormone (1-34) on fractures and bone density in postmenopausal women with osteoporosis.
NEJM, 344 (2001), pp. 1434-1441
[99.]
R. Prince, A. Sipos, A. Hossain, U. Syversen, S. Ish-Shalom, E. Marcinowaska, et al.
Sustained non vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
J Bone Min Res, 20 (2005), pp. 1507-1513
[100.]
D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, et al.
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
NEJM, 349 (2003), pp. 1207-1215
[101.]
D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, M.A. Trisha Hue, et al.
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
NEJM, 353 (2005), pp. 555-565
[102.]
P.J. Marie.
Strontium ranelate: New insights into its dual mode of action.
Bone, 40 (2007), pp. s5-s8
[103.]
C. Roux.
Antifracture efficacy of strontium ranelate in postmenopausal osteoporosis.
Bone, 40 (2007), pp. s9-s11
[104.]
J.Y. Reginster, E. Seeman, M.C. De Vernejoul, S. Adami, J. Compston, C. Phenekos, et al.
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study.
J Clin Endocrinol Metabol, 90 (2005), pp. 2816-2822
[105.]
D. Shoback.
Update in osteoporosis and metabolic bone disorders.
J Clin Endocrinol Metabol, 92 (2007), pp. 747-753
Copyright © 2010. Asociación Colombiana de Reumatología
